Looking for an edge in the wet AMD market, phase 3 biotech Opthea guns for $150M IPO

Looking for an edge in the wet AMD market, phase 3 biotech Opthea guns for $150M IPO

Submitted by admin on September 25, 2020 - 10:35am
Source: 
Fierce Biotech
News Tags: 
Opthea
IPOs
wet age-related macular degeneration
Headline: 
Looking for an edge in the wet AMD market, phase 3 biotech Opthea guns for $150M IPO
snippet: 

Australian eye disease biotech Opthea is seeking out a meaty $150 million IPO as it looks to clear a late-stage clinical hurdle and become a commercial company.

Do Not Allow Advertisers to Use My Personal information